RxDoctor Payments Data

Meagan Wilson

General Practice · Dawsonville, GANPI 1881140598

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 408 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,854in general payments, 2019–2025

Across 408 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$597
  • Otsuka America Pharmaceutical, Inc.$480
  • Novo Nordisk$458
  • Pfizer$266
  • Novartis$251
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$6,824100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,854 in reported general payments places this provider in the 95th percentile of 2,542 general practice providers in Georgia.

See all general practice providers in Georgia

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$58,005
FarxigaDapagliflozin Propanediol43$29,037
MounjaroTirzepatide26$27,038
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$26,340
TrulicityDulaglutide26$24,093
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$19,922
Repatha SureclickEvolocumab22$17,110
VascepaIcosapent Ethyl21$11,943
Repatha SyringeEvolocumab18$11,003
LinzessLinaclotide16$10,973
Emgality SyringeGalcanezumab-Gnlm11$7,817
TrintellixVortioxetine Hydrobromide16$7,628
BelsomraSuvorexant16$7,135
MyrbetriqMirabegron16$7,091
Ibuprofen-FamotidineIbuprofen/Famotidine17$3,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$458$58,00554 claims
Lilly USA, LLCMounjaro, Trulicity$225$51,13152 claims
AstraZenecaFarxiga, Breztri Aerosphere$112$48,95968 claims
GSKTrelegy Ellipta, Shingrix$207$28,94149 claims
AbbVieLinzess$1,222$10,97316 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$152$7,62816 claims
MerckBelsomra$75$7,13516 claims
Astellas Pharma US IncMyrbetriq$49$7,09116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,542 general practice providers in Georgia.

Other general practice in Dawsonville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →